MacroGenics

$22.43
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.26 (-5.32%) As of 4:41 PM UTC today

Why Robinhood?

You can buy or sell MacroGenics and other stocks, options, and ETFs commission-free!

About MGNX

MacroGenics, Inc. Common Stock, also called MacroGenics, is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD. The listed name for MGNX is MacroGenics, Inc. Common Stock.

CEO
Scott E. Koenig
Employees
384
Headquarters
Rockville, Maryland
Founded
2000
Market Cap
1.25B
Price-Earnings Ratio
Dividend Yield
Average Volume
433.40K
High Today
$24.26
Low Today
$22.16
Open Price
$23.72
Volume
140.48K
52 Week High
$32.18
52 Week Low
$4.04

Collections

MGNX Earnings

-$1.02
-$0.68
-$0.34
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 23, After Hours

You May Also Like